CN112153980A - 包含葡萄球菌抗原的免疫原性组合物 - Google Patents

包含葡萄球菌抗原的免疫原性组合物 Download PDF

Info

Publication number
CN112153980A
CN112153980A CN201980025676.7A CN201980025676A CN112153980A CN 112153980 A CN112153980 A CN 112153980A CN 201980025676 A CN201980025676 A CN 201980025676A CN 112153980 A CN112153980 A CN 112153980A
Authority
CN
China
Prior art keywords
seq
amino acid
immunogenic composition
acid sequence
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980025676.7A
Other languages
English (en)
Chinese (zh)
Inventor
F·巴格诺利
C·戈拉吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of CN112153980A publication Critical patent/CN112153980A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201980025676.7A 2018-02-13 2019-02-12 包含葡萄球菌抗原的免疫原性组合物 Pending CN112153980A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1802339.0A GB201802339D0 (en) 2018-02-13 2018-02-13 Immunogenic composition
GB1802339.0 2018-02-13
PCT/EP2019/053463 WO2019158537A1 (en) 2018-02-13 2019-02-12 Immunogenic composition comprising staphylococcal antigens

Publications (1)

Publication Number Publication Date
CN112153980A true CN112153980A (zh) 2020-12-29

Family

ID=61731342

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980025676.7A Pending CN112153980A (zh) 2018-02-13 2019-02-12 包含葡萄球菌抗原的免疫原性组合物

Country Status (15)

Country Link
US (2) US11426455B2 (https=)
EP (1) EP3752183A1 (https=)
JP (1) JP2021514387A (https=)
KR (1) KR20200121825A (https=)
CN (1) CN112153980A (https=)
AR (1) AR114627A1 (https=)
AU (1) AU2019221496B2 (https=)
BR (1) BR112020016373A2 (https=)
CA (1) CA3090609A1 (https=)
EA (1) EA202091690A1 (https=)
GB (1) GB201802339D0 (https=)
IL (1) IL276661B2 (https=)
MX (1) MX2020008454A (https=)
SG (1) SG11202007676RA (https=)
WO (1) WO2019158537A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201721582D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
CN110511950B (zh) * 2019-07-29 2022-03-08 因之彩生物科技（武汉）有限公司 Pab蛋白在构建具有类伴侣样蛋白作用的融合蛋白表达载体中的应用
EP3777884A1 (en) * 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
WO2021122551A1 (en) 2019-12-19 2021-06-24 Glaxosmithkline Biologicals Sa S. aureus antigens and compositions thereof
MY207887A (en) * 2020-05-01 2025-03-26 Sinocelltech Ltd Method for improving immunogenicity of protein/peptide antigen
JP7423133B2 (ja) 2020-09-21 2024-01-29 エルジー エナジー ソリューション リミテッド リチウム二次電池の活性化方法及びリチウム二次電池

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101128215A (zh) * 2004-09-22 2008-02-20 葛兰素史密丝克莱恩生物有限公司 用于进行抗葡萄球菌接种的免疫原性组合物
CN102481352A (zh) * 2009-06-22 2012-05-30 惠氏有限责任公司 金黄色葡萄球菌抗原的免疫原性组合物
CN103037885A (zh) * 2010-07-02 2013-04-10 芝加哥大学 与蛋白A（SpA）变体相关的组合物和方法
CN103079591A (zh) * 2010-05-06 2013-05-01 格林考瓦因有限公司 荚膜革兰氏阳性细菌生物缀合物疫苗
CN104736165A (zh) * 2012-08-31 2015-06-24 诺华股份有限公司 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0526038D0 (en) 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
SG188102A1 (en) * 2008-01-31 2013-03-28 Trinity College Dublin Treatment of microbial infections
AU2015202532A1 (en) 2009-04-14 2015-06-04 Novartis Ag Compositions for immunising against Staphylococcus aureus
US20140037650A1 (en) 2009-07-24 2014-02-06 University Of Chicago Compositions and methods related to antibodies to staphylococcal proteins isda or isdb
EP2614074A1 (en) 2010-09-09 2013-07-17 The University of Chicago Methods and compositions involving protective staphylococcal antigens
EP2654784B1 (en) 2010-12-22 2016-12-07 Wyeth LLC Stable immunogenic compositions of staphylococcus aureus antigens
BR112014003315A2 (pt) * 2011-08-15 2017-03-01 Univ Chicago composições e métodos relacionados a anticorpos para a proteína a estafilocócica
US10195262B2 (en) 2013-12-04 2019-02-05 Glaxosmithkline Biologicals S.A. Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli
CN106103469B (zh) * 2014-03-26 2020-11-27 葛兰素史密丝克莱恩生物有限公司 突变型葡萄球菌抗原
GB201721576D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
GB201721582D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101128215A (zh) * 2004-09-22 2008-02-20 葛兰素史密丝克莱恩生物有限公司 用于进行抗葡萄球菌接种的免疫原性组合物
CN102481352A (zh) * 2009-06-22 2012-05-30 惠氏有限责任公司 金黄色葡萄球菌抗原的免疫原性组合物
CN103079591A (zh) * 2010-05-06 2013-05-01 格林考瓦因有限公司 荚膜革兰氏阳性细菌生物缀合物疫苗
CN103037885A (zh) * 2010-07-02 2013-04-10 芝加哥大学 与蛋白A（SpA）变体相关的组合物和方法
CN104736165A (zh) * 2012-08-31 2015-06-24 诺华股份有限公司 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质

Also Published As

Publication number Publication date
US11426455B2 (en) 2022-08-30
EA202091690A1 (ru) 2020-11-27
US20230052495A1 (en) 2023-02-16
WO2019158537A1 (en) 2019-08-22
KR20200121825A (ko) 2020-10-26
IL276661B2 (en) 2023-08-01
EP3752183A1 (en) 2020-12-23
US20210023192A1 (en) 2021-01-28
MX2020008454A (es) 2021-03-25
AR114627A1 (es) 2020-09-30
CA3090609A1 (en) 2019-08-22
AU2019221496B2 (en) 2022-12-08
AU2019221496A1 (en) 2020-08-27
BR112020016373A2 (pt) 2020-12-15
GB201802339D0 (en) 2018-03-28
IL276661A (en) 2020-09-30
IL276661B1 (en) 2023-04-01
SG11202007676RA (en) 2020-09-29
JP2021514387A (ja) 2021-06-10

Similar Documents

Publication Publication Date Title
US20230052495A1 (en) Immunogenic composition comprising staphylococcal antigens
CN107602676B (zh) OspA的突变片段以及其相关方法和用途
KR20120093141A (ko) 폐렴구균(Ｓｔｒｅｐｔｏｃｏｃｃｕｓ Ｐｎｅｕｍｏｎｉａｅ)에 대항하는 백신과 조성물
CN106103469B (zh) 突变型葡萄球菌抗原
CN101107009B (zh) 包含纤连蛋白结合蛋白或纤连蛋白结合肽的疫苗组合物
JP2021528059A (ja) グリコシル化されたＣｏｍＰピリンバリアント、製造方法及びその使用
JP2021506318A (ja) 免疫原性組成物
JP2024540918A (ja) リポ多糖（ｌｐｓ）欠損アシネトバクター・バウマニ多価ワクチン
US20150023983A1 (en) Recombinant vapa and vapc peptides and uses thereof
US20220395566A1 (en) Immunogenic composition
US12472249B2 (en) Glyconjugate vaccines
HK40047921A (en) Mutant staphylococcal antigens
JP2019182751A (ja) ネオスポラ原虫感染症に対するワクチン製剤
HK1207982B (en) Mutant fragments of ospa and methods and uses relating thereto

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201229

WD01 Invention patent application deemed withdrawn after publication